Nevolat (Liraglutide)

Liraglutide, the active ingredient in Nevolat, is a GLP-1 receptor agonist presented as an injectable solution for subcutaneous use. The molecule mimics the endogenous incretin hormone glucagon-like peptide-1, enhancing glucose-dependent insulin secretion while reducing appetite. It is indicated for the management of type 2 diabetes mellitus and for obesity treatment in adult patients.

GNH USA supplies Nevolat as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, delivering the product across multiple continents with strict quality assurance.

Nevolat (liraglutide) acts on the GLP-1 pathway to improve metabolic control in several chronic conditions.

- Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Obesity: promotes weight loss by decreasing appetite and caloric intake. - Cardiovascular risk reduction: lowers incidence of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Nevolat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Injection site reactions

Serious or Rare Side Effects: - Pancreatitis - Gallbladder disease (including cholelithiasis) - Thyroid C-cell tumors (observed in rodent studies) - Acute kidney injury

When prescribing Nevolat, clinicians should consider several safety precautions to minimize risk.

- Renal function: assess kidney status before initiation and monitor periodically. - Pancreatitis: discontinue if severe abdominal pain with elevated enzymes occurs. - Thyroid disease: avoid in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. - Pregnancy and lactation: use only if potential benefit justifies potential risk to the fetus or infant. - Drug interactions: adjust doses of insulin or sulfonylureas to prevent hypoglycemia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Liraglutide can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Insulin: increased risk of severe hypoglycemia. - Sulfonylureas: heightened hypoglycemia potential. - Medications that cause gastrointestinal irritation: may exacerbate nausea.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR. - Thiazolidinediones: additive weight gain. - Beta‑blockers: may mask hypoglycemia symptoms.